Category - Developments

Developments

Kane Biotech fulfills first major animal oral care product order from China

Kane Biotech (TSX-V:KNE) fulfilled its first major order, for $125,000 in bluestem pet oral care products, to its exclusive Chinese distribution partner, Eetoys Pet Products. Kane announced the exclusive distribution...

December 17, 2019

Developments

Avadel Pharma completes enrollment in Phase 3 narcolepsy trial

Avadel Pharmaceuticals (NASDAQ:AVDL) completed enrollment in its pivotal trial assessing FT218 for excessive daytime sleepiness and cataplexy in patients with narcolepsy. The Phase 3 study, called REST-ON, enrolled 212...

December 17, 2019

Developments

Pacira reports positive Phase 3 results for long-acting local analgesic in pediatric patients

Pacira BioSciences (NASDAQ:PCRX) reported positive results from its Phase 3 study of EXPAREL in pediatric patients undergoing spinal or cardiac surgeries. EXPAREL is a non-opioid, single-dose, long-acting local...

December 17, 2019

Developments

Eiger initiates rolling NDA for progeria drug candidate

Eiger BioPharmaceuticals (NASDAQ:EIGR) initiated a rolling NDA submission to the FDA for lonafarnib for the treatment of Hutchinson-Gilford progeria syndrome and progeroid laminopathies. Progeria is an extremely rare...

December 17, 2019

Developments

Kamada enrolls first patient in Phase 3 alpha-1 antitrypsin deficiency trial

Kamada (NASDAQ, TASE:KMDA) randomized the first patient in a pivotal clinical trial evaluating its inhaled alpha-1 antitrypsin (AAT) therapy for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is an...

December 17, 2019

Developments

Kane Biotech launches anti-biofilm shampoo consumer product test

Kane Biotech (TSX-V:KNE) launched a consumer product test to evaluate the efficacy of its new shampoo on dermatitis and dandruff. Research indicates that microbial biofilms may aggravate symptoms associated with...

December 16, 2019

Developments

OncoSec presents interim Phase 2 data in metastatic triple negative breast cancer

OncoSec Medical (NASDAQ:ONCS) presented interim results from KEYNOTE-890, an ongoing Phase 2 study of its TAVO drug candidate in combination with KEYTRUDA in patients with metastatic, chemotherapy-refractory triple...

December 13, 2019

Developments

BriaCell announces clinical data at 2019 San Antonio Breast Cancer Symposium

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) presented results of clinical studies with its lead product candidate, Bria-IMT, in combination with immune checkpoint inhibitors in advanced breast cancer at 2019 San...

December 13, 2019

Developments

Soricimed updates peptide-drug conjugate program

Closely-held Soricimed Biopharma updated its peptide-drug conjugate (PDC) program, which enables delivery of a cytotoxic drug payload bound to a targeting peptide directly to receptors that are overexpressed by cancer...

December 12, 2019

Developments

Hepion advances to next dosing level in ongoing Phase 1 study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) advanced to the next higher dose of CRV431 in its ongoing Phase 1 multiple ascending dose trial in healthy volunteers. The clinical trial management team determined the 75 mg dosing...

December 10, 2019

Category - Developments

Subscribe